MX390677B - Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina - Google Patents

Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina

Info

Publication number
MX390677B
MX390677B MX2019013970A MX2019013970A MX390677B MX 390677 B MX390677 B MX 390677B MX 2019013970 A MX2019013970 A MX 2019013970A MX 2019013970 A MX2019013970 A MX 2019013970A MX 390677 B MX390677 B MX 390677B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
release pharmaceutical
amphetamine
delayed sustained
delayed
Prior art date
Application number
MX2019013970A
Other languages
English (en)
Other versions
MX2019013970A (es
Inventor
Alexander Brian Lippold
Jae Han Park
Rebecca Sue Walker
Tsz Chung Lai
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2019013970A publication Critical patent/MX2019013970A/es
Publication of MX390677B publication Critical patent/MX390677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas de liberación sostenida retardada que proporcionan efectos terapéuticos en períodos de tiempo prolongados (es decir, 14-16 horas).
MX2019013970A 2017-06-14 2018-06-07 Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina MX390677B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762519351P 2017-06-14 2017-06-14
PCT/US2018/036424 WO2018231619A1 (en) 2017-06-14 2018-06-07 Delayed sustained release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2019013970A MX2019013970A (es) 2020-02-10
MX390677B true MX390677B (es) 2025-03-21

Family

ID=64655979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013970A MX390677B (es) 2017-06-14 2018-06-07 Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina

Country Status (12)

Country Link
US (1) US11033508B2 (es)
EP (1) EP3638211B1 (es)
JP (1) JP6990719B2 (es)
AU (1) AU2018286535B2 (es)
BR (1) BR112019024708A2 (es)
CA (1) CA3064891A1 (es)
DK (1) DK3638211T3 (es)
ES (1) ES2967488T3 (es)
HU (1) HUE065294T2 (es)
MX (1) MX390677B (es)
PL (1) PL3638211T3 (es)
WO (1) WO2018231619A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024708A2 (pt) 2017-06-14 2020-06-09 SpecGx LLC composições farmacêuticas de liberação prolongada retardada
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0886519A1 (en) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
WO2006138227A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
MX2008014455A (es) 2006-05-12 2008-11-27 Shire Llc Sistema de suministro de farmaco de dosis controlada.
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
BR112019024708A2 (pt) 2017-06-14 2020-06-09 SpecGx LLC composições farmacêuticas de liberação prolongada retardada

Also Published As

Publication number Publication date
DK3638211T3 (da) 2024-01-22
EP3638211A1 (en) 2020-04-22
CA3064891A1 (en) 2018-12-20
JP2020523290A (ja) 2020-08-06
US20180360764A1 (en) 2018-12-20
EP3638211A4 (en) 2021-03-24
EP3638211B1 (en) 2023-11-29
MX2019013970A (es) 2020-02-10
WO2018231619A1 (en) 2018-12-20
AU2018286535B2 (en) 2023-08-17
US11033508B2 (en) 2021-06-15
BR112019024708A2 (pt) 2020-06-09
HUE065294T2 (hu) 2024-05-28
ES2967488T3 (es) 2024-04-30
PL3638211T3 (pl) 2024-04-15
JP6990719B2 (ja) 2022-01-12
AU2018286535A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
EP3644740A4 (en) AGRICULTURAL COMPOSITIONS
MX2016011072A (es) Derivado de pirazol amida.
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
EP4125815A4 (en) Therapeutic compositions
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
TN2018000351A1 (en) Oxaborole esters and uses thereof
EP4072553A4 (en) Cariprazine release formulations
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
CL2017000074A1 (es) Antagonistas de reproducción de peces
EP4241729A4 (en) DENTAL PROSTHESIS ATTACHMENT
MX388559B (es) Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.
CL2017000153A1 (es) Composiciones de azúcares para la formación de comprimidos mediante compresión directa
EP3868371A4 (en) Novel pharmaceutical composition
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
MX376741B (es) Composición farmaceútica de sulfonamida
MX390677B (es) Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina
DK3908321T3 (da) Farmaceutisk sammensætning
PT3949952T (pt) Composição farmacêutica